Abstract:Clinical studies reported that Type 2 diabetes mellitus (T2DM) is associated with increased risk of cognitive impairment and dementia including Alzheimer's disease (AD). We previously reported that T2DM model mice, KKAy, exhibit cognitive impairment compared with wild-type mice. However, therapeutical approach for T2DM-induced cognitive decline has not been well investigated. Central role of renin-angiotensin system (RAS) has been highlighted. RAS is considered to function with various neurotransmitters for learning and memory. Recently, interaction between angiotensin receptors and N-Methyl-D-aspartic acid (NMDA) glutamate receptors has been reported. We previously reported that angiotensin II type 2 (AT 2) receptor affects cognitive function and a direct AT 2 receptor agonist, compound 21 (C21), enhances cognitive function in wild-type mice. Here, we investigated the possibility of the therapeutic approach with memantine and C21 on T2DM-induced cognitive impairment. Ten week-old male KKAy mice were separated into four groups; 1) control, 2) 10 m g/kg/day C21 treatment 3) 20 mg/kg/day memantine treatment 4) treatment with both memantine and C21. Memantine and C21 were administrated by oral and intraperitoneal injection, respectively. Mice were subjected to the Morris water maze task for 5 days. Cerebral blood flow (CBF) was analyzed by laser speckle flowmetry after the cognitive task. Phosphorylation of NMDA receptors was accessed by immunoblot. Blood pressure and body weight were not different among all groups. In the Morris water maze, escape latency was shortened in C21 treatment group compared with control group. Interestingly, co-treatment with memantine significantly further shortened swim latency in C21-treated KKAy. CBF was increased in C21-treated group compared with control group. We investigated the effect of C21 on NMDA phosphorylation after water maze, and observed that treatment with C21 enhanced NMDA phosphorylation in the hippocampus. These results suggest that direct AT 2 receptor stimulation has a protective effect on cognitive decline in the Morris water maze in T2DM mice. Co-administration of memantine enhanced a C21-induced preventive effect, indicating that RAS is involved in memory and learning system by the interaction with neurotransmitter for NMDA receptor. Therefore, regulation of RAS may be a new strategy for diabetes-induced cognitive decline including AD.

Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia

Caffeine protects against hippocampal alterations in type 2 diabetic rats via modulation of gliosis, inflammation and apoptosis

A Novel Thiazolidinediones ATZD2 Rescues Memory Deficits in a Rat Model of Type 2 Diabetes Through Antioxidant and Anti-Inflammation

Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis

Carnosine-based reversal of diabetes-associated cognitive decline via activation of the Akt/mTOR pathway and modulation of autophagy in a rat model of type 2 diabetes mellitus

Neurobehavioral and neurobiochemical effect of atomoxetine and N-acetylcysteine in streptozotocin diabetes induced endothelial dysfunction and related dementia

Preventive Effect of Caffeine on Alzheimer's Disease

Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway

P4‐206: Co‐treatment with Memantine and Compound 21, an Angiotensin II Type 2 Receptor Agonist, Prevents Cognitive Decline in Type 2 Diabetic Mice

Combined Effect of Co-administration of Stromal Cell-Derived Factor-1 and Granulocyte-Colony Stimulating Factor on Rat Model of Alzheimer’s Disease

Anti-Alzheimer Activity of Combinations of Cocoa with Vinpocetine or Other Nutraceuticals in Rat Model: Modulation of Wnt3/β-Catenin/GSK-3β/Nrf2/HO-1 and PERK/CHOP/Bcl-2 Pathways

Aerobic exercise combined with chlorogenic acid exerts neuroprotective effects and reverses cognitive decline in Alzheimer’s disease model mice (APP/PS1) via the SIRT1/ /PGC-1α/PPARγ signaling pathway

AMPK activation ameliorates Alzheimer's disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer's disease model in rats

Co-treatment with memantine and compound 21, an angiotensin II type 2 receptor agonist, prevents cognitive decline in type 2 diabetic mice

Possible Synergistic Effect of Direct Angiotensin II Type 2 Receptor Stimulation by Compound 21 with Memantine on Prevention of Cognitive Decline in Type 2 Diabetic Mice

Potential of Caffeine in Alzheimer’s Disease—A Review of Experimental Studies

Zonisamide Ameliorates Cognitive Impairment by Inhibiting ER Stress in a Mouse Model of Type 2 Diabetes Mellitus

Treatment with Blackberry Extract and Metformin in Sporadic Alzheimer's Disease Model: Impact on Memory, Inflammation, Redox Status, Phosphorylated Tau Protein and Insulin Signaling

Ameliorative Effect of Allantoin, Beta cyclodextrin and Combination of Both against Diabetic Cognitive Impairment

Combined Metabolic Activators with Different NAD+ Precursors Improve Metabolic Functions in the Animal Models of Neurodegenerative Diseases

Therapeutic effects of alpha lipoic acid and/or caffeine-loaded chitosan nanoparticles on memory impairment and neurochemical changes in high-fat diet-induced obese rats